Aligos Therapeutics (ALGS) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TScan Therapeutics (TCRX) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 84.8% versus a loss of 86.8%. Over five years, TCRX leads with a -98.3% price change compared with -99.7% for ALGS. TScan Therapeutics is the larger company by market cap ($9.9 million vs $7.6 million), about 1.3 times the size.
Aligos Therapeutics converts more of its revenue into profit, with a net margin of -1106.7% versus -1256.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | TCRX |
|---|---|---|
| Share price | $1.22 | $0.1459 |
| Market cap | $7.62M | $9.89M |
| 1-day change | -2.40% | +2.24% |
| YTD return | -86.91% | -85.41% |
| 1-year return | -86.75% | -84.85% |
| 5-year return | -99.70% | -98.33% |
| EPS (TTM) | $-6.46 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.19M | $10.32M |
| Revenue growth (YoY) | -39.46% | +266.65% |
| Net income (latest FY) | $-24.19M | $-129.77M |
| Operating margin | -4024.93% | -1315.38% |
| Net margin | -1106.72% | -1256.81% |
| 52-week high | $13.69 | $1.47 |
| 52-week low | $1.18 | $0.14 |
| Distance from 52-week high | -91.09% | -90.07% |
| Analyst consensus | none | hold |
| Avg. price target upside | +4193.44% | +585.40% |
| Average volume | 57.37K | 766.11K |
| Shares outstanding | 5.45M | 63.50M |
| Employees | 82 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Aligos Therapeutics is more profitable, keeping -1106.7 cents of every revenue dollar as net income versus -1256.8 cents for TScan Therapeutics.
- TScan Therapeutics grew revenue faster in its latest fiscal year (+266.65% vs -39.46%).
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
ALGS vs TCRX FAQ
Which is bigger, Aligos Therapeutics or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $9.89M compared with $7.62M for Aligos Therapeutics (ALGS).
Which stock has performed better over the past year, ALGS or TCRX?
TCRX returned -84.85% over the past 12 months, compared with -86.75% for ALGS (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.